Implementation of the technique for detection of transcripts of the BCR-ABR fusion gene

For several decades, the detection and study of cytogenetic abnormalities has been carried out through chromosomal analysis or mapping; Currently, molecular biology based on the polymerase chain reaction (PCR) have allowed to identify more than 50 chromosomal translocations, many of which have proven to be specific for different subtypes of leukemia. Myeloproliferrative diseases have not been the exception, within these chronic myeloid leukemia that affects a considerable percentage of our population and is associated with the presence of the BCR-Ab-lable fusion gene related to the philadelphia chromosome (PH). One of the most used techniques for the detection of this merger gene is the PCR with reverse transcription, through which from the messenger RNA sequences it is possible to detect transcripts, this technique shows greater sensitivity and specificity than the cytogenetic study contributing to the diagnosis and prognosis of these pathologies, as well as performing a monitoring to identify response to treatment and detection of minimal residual disease (EMR). The importance of this research is that at present, thanks to recent advances in the molecular pathogenesis of cancer, therapeutic behaviors based on molecular therapies have been developed, aimed at patients with leukemias who do not respond to conventional treatment, where blockers have been used, improving the patient's quality of life, as well as the time of remission of the disease.

STRENGTHENING RESEARCH GROUPS